Table 2.
Changes in clinical parameters for oMGD patients between before and 4 or 8 weeks after the onset of maxacalcitol treatment
| Parameter | Pretreatment | 4 weeks | 8 weeks |
|---|---|---|---|
| Ocular symptoms | 6.9 ± 2.5 | 4.0 ± 1.2 (0.001) | 2.2 ± 1.3 (<0.001) |
| Plugging of gland orifices (0–3) | 1.8 ± 0.8 | 0.9 ± 0.7 (0.070) | 0.4 ± 0.5 (<0.001) |
| Lid margin irregularity (0–2) | 1.0 ± 0.6 | 0.8 ± 0.4 (0.597) | 0.8 ± 0.4 (0.597) |
| Lid margin vascularity (0–3) | 1.3 ± 0.5 | 0.6 ± 0.5 (0.020) | 0.6 ± 0.5 (0.020) |
| MCJ replacement (0–3) | 1.0 ± 0.6 | 0.8 ± 0.4 (0.633) | 0.7 ± 0.5 (0.197) |
| BUT (s) | 2.9 ± 1.4 | 4.2 ± 1.7 (0.163) | 5.4 ± 2.2 (0.030) |
| SPK score (0–9) | 0.5 ± 0.5 | 0.3 ± 0.5 (0.519) | 0.5 ± 0.0 (0.011) |
| Meibum grade (0–3) | 2.0 ± 1.0 | 1.3 ± 0.8 (0.105) | 0.8 ± 0.8 (0.020) |
| Schirmer test value (mm) | 6.5 ± 1.1 | 6.9 ± 1.0 (0.548) | 6.6 ± 1.1 (0.974) |
| Mean meibomian gland area (%) | 24.0 ± 8.3 | 27.7 ± 7.3 (0.399) | 32.8 ± 7.5 (0.017) |
Values in parentheses are P values for comparison with the corresponding pretreatment data (one-way ANOVA followed by Dunnett’s test)